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Conclusions: We have demonstrated that treatment with CS is capable
to reduce PBMC inﬂammation in rabbits in which chronic arthritis aggra-
vates vascular lesions associated to atherosclerosis. CS evoked a clear
improvement in the inﬂammatory response of the synovial membrane,
as well as a decrease in the synovial histopathological lesions. Our
results suggest that this drug may have beneﬁcial effects on the treatment
of inﬂammatory synovitis probably acting through the NFkB depending
pathway.
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Purpose: Il-1b and TNF-a are cytokines that have always been grouped
into the pro-inﬂammatory cytokine class. In some pathologic scenarios,
as in apoptotic environment, chondrocytes respond in a different way de-
pending on what cytokine is present. It is not clear the exact mechanisms
by they exercise their different functions in the chondrocyte. The present
study, analyzes the differences in protein expression patterns between
both cytokines in order to understand the development of rheumatic
pathologies.
Methods: Human normal chondrocytes were isolated from cartilage ob-
tained from autopsies without history of joint disease. Chondrocytes were
incubated for 48 hours in basal conditions, with Il-1b (5 ng/ml) or TNF-
a (10 ng/ml), and cellular protein extracts were obtained. A pool of four
patients in each condition, by duplicate, was made and resolved by 2-DE.
Protein spots were visualized with Sypro for comparative analyses or
with Coomassie stain for protein identiﬁcation. Qualitative and quantitative
analysis were made with PD-QUEST software. After that, protein spots
were identiﬁed by mass spectrometry using MALDI-TOF/TOF technology.
Validation of identiﬁed spots was made by real time PCR, western blot
and inmunoﬂuorescence.
Results: Different comparative analyses were made in the spots that
were matched in every member. We compared protein proﬁles between
basal and Il-1b, basal and TNF-a and between Il-1b and TNF-a conditions.
We found a different regulation in the expression ratios of cytoskeleton
proteins, modulation of transcription, metabolism, energy production and
stress responses between basal and Il-1b as well as, basal and TNF-a
stimulated cells. In addition to this, comparing both cytokines, this table
shows the qualitative differences in terms of presence (+) or absence (−),
between Il-1b and TNF-a conditions. Also, quantitative differences were
found in Tryptophanil tRNA synthethase, Translation initiation factor 3,
Interferon-induced GTP-binding protein and Argininosuccinate synthase,
that were up-regulated more than two fold in the TNF-a treated cells,
respect to Il-1b condition. On the other hand, proteins such as Antisense
basic ﬁbroblast growth factor or Triose phosphate isomerise, were down-
regulated in the TNF-a situation with a ratio of 0.4 (where Il-1b=1).
These differences affect principally to metabolic chondrocyte activity,
transcription and protein modiﬁcations.
PROT PAR12 P58 PSB3 PSME2 LDHB ACSL4 PBEF MDHM G3P ENOA MATN ANX5
TNFa/Il-1b −/+ −/+ +/− −/+ −/+ −/+ −/+ −/+ −/+ +/− −/+ −/+
Conclusions: Our studies indicate that the cytokines, Il-1b and TNF-a,
have different protein expression patterns in human normal chondrocytes
in culture. This study will help us to understand the role that each member
plays in pathologic processes that affects chondrocytes.
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Purpose: Aggrecanase cleavage at the 373Glu-374Ala bond in the inter-
globular domain of aggrecan, releasing N-terminal 374ARGS fragments,
is an early key event in arthritis and joint injuries. Here we quantify the
levels of aggrecan and aggrecan ARGS fragments in synovial ﬂuid from
knee healthy subjects and from patients with acute arthritis, knee injury
and knee osteoarthritis (OA) with the aim of verifying the pathological role
of aggrecanase cleavage at this site.
Methods: Knee synovial ﬂuid (SF) from 26 knee healthy individuals
(REF) and 269 patients were obtained in a cross sectional study. Patient
groups were acute arthritis (AA; n = 48), knee injury (KI; n = 192) and
OA (n = 29). The KI group was divided into three subgroups by time
after injury: 0−8 weeks (KI-1; n = 64), 9−52 weeks (KI-2; n = 58) and
>1 year (KI-3; n = 70). Aggrecan fragments with the N-terminal 374ARGS
were assayed by ELISA using a monoclonal antibody (OA-1). Total
aggrecan content was analyzed by an Alcian blue precipitation method
measuring sulfated glycosaminoglycan (sGAG) and by an ELISA using
the monoclonal antibody 1-F21 recognizing a peptide sequence in the
keratan sulfate domain. Kruskal-Wallis one way analysis of variance on
rank (Dunn’s method) was used for multiple group comparisons; P< 0.05
was considered signiﬁcant. Spearman rank order correlation (rS) was
used for comparisons.
Results: Median concentrations of aggrecan ARGS fragments (pmol/ml
SF) were elevated in all groups compared to the REF (Table I). The largest
elevation (177-fold) was seen in the acute arthritis group, while the knee
injury group had a 13-fold elevation and the OA group a 9-fold elevation.
Subdivision of the knee injury group showed that elevation of the ARGS
concentration in the knee injury group all occurred in the time span of
0−8 weeks after injury (KI-1) which was 130-fold elevated compared to
the reference. The release of ARGS fragments into the synovial ﬂuid
thereafter did not differ from REF. The SF ARGS concentration correlated
positively with the overall aggrecan content measured by Alcian blue
precipitation (rS = 0.687) and by the 1-F21 ELISA (rS = 0.667). In contrast
to the results of the ARGS immunoassay, when using the Alcian Blue
precipitation method only the AA and KI-1 groups differed in aggrecan
concentration from the REF group, and no differences between groups
were seen when using the 1-F21 assay (Table I).
Conclusions: The observed differences in ARGS concentration in syn-
ovial ﬂuid between the diagnostic groups showed that the aggrecanase
cleavage at the 373Glu-374Ala bond in the interglobular domain of ag-
grecan is enhanced in joint pathology, most markedly in acute arthritis
and early after knee injury, but also in knee OA. In contrast to methods
quantifying human SF total aggrecan (e.g. by sGAG measurements),
quantiﬁcation of ARGS fragments generated by aggrecanases is clearly
a more powerful tool in distinguishing healthy from diseased and injured
joints. The ARGS ELISA method could be used for monitoring disease
progression, predicting clinical outcomes and following the effects of
treatment.
Table I: Human SF median concentrations (ranges) of ARGS, sGAG and aggrecan
ARGS ELISA Alcian blue precipitation 1-F21 ELISA
Diagn
groups
n pmol
ARGS/ml
Fold
diff
P < 0.05 n mg
sGAG/ml
Fold
diff
P < 0.05 n mg aggrecan/
ml
Fold
diff
P < 0.05
REF 26 0.5
(0.5−3.3)
1 na 26 61
(5−210)
1 na 22 132
(20−558)
1 na
AA 48 88.5
(0.5−961)
177 Y 47 88
(112−528)
1.44 Y 45 261
(12−1912)
1.98 N
1KI 192 6.6
(0.5−946)
13 Y 191 74
(5−728)
1.21 N 189 104
(0.2−1340)
0.79 N
KI-1 64 64.9
(0.5−946)
130 Y 64 121
(39−728)
1.98 Y 62 178
(44−1340)
1.35 N
KI-2 58 0.5
(0.5−266)
1 N 58 63
(16−317)
1.03 N 57 87
(14−759)
0.66 N
KI-3 70 0.5
(0.5−166)
1 N 69 59
(5−245)
0.97 N 70 87
(0.2−791)
0.66 N
OA 29 4.6
(0.5−318)
9 Y 29 58
(8−201)
0.95 N 29 127
(12−482)
0.96 N
REF, knee healthy reference; AA, acute arthritis; KI, knee injury; KI-1, knee injury subgroup (SF aspiration
0−8 weeks after injury); KI-2, knee injury subgroup (SF aspiration 9−52 weeks after injury); KI-3, knee injury
subgroup (SF aspiration >52 weeks after injury); OA, knee osteoarthritis.
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Purpose: The pathogenesis of osteoarthritis (OA) is a complicated line
of events in the whole joint, eventually leading to pain and disability. Pain
is one of the most critical symptoms of osteoarthritis (OA) and a central
clinical end goal. However, the sources of pain are elusive and not well
understood – making treatment development challenging. Furthermore,
precise quantiﬁcation of pain is challenging in clinical trials, causing sur-
rogate markers to be desirable. We investigated the association between
pain and knee cartilage markers from magnetic resonance imaging (MRI)
as well as biochemical markers of bone and cartilage turnover.
